Fig. 1 · Structure

Documents & Downloads

SL 0101-1

Cat. No. A11160 CAS 77307-50-7

RSK Inhibitor

SL 0101-1 is a selective inhibitor of p90 ribosomal S6 kinase (RSK) (IC50 = 89 nM for RSK2). It also inhibits the growth of MCF-7 human breast cancer cells with no effect on the normal breast cell line.

In Stock

Publications for SL 0101-1

1 publication citing this product

  1. Pirbhoy PS, .et al. , Learn Mem, 2017, Aug; 24(8): 341-357 PMID: 28716954

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Biological Activity

Bioactivity / Mechanism

SL0101 binds the N-terminal kinase domain of RSK2. In a murine-domain crystal structure, binding was associated with rearrangement of the nucleotide-binding cleft into a hydrophobic pocket accommodating the inhibitor. [1]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

Target & Activity

Target Activity Value
RSK1  

Cellular Effect

Cell Line Activity Value Description Reference
HCC70 IC50 15 μM Anticancer activity against human HCC70 cells assessed as cell growth inhibition incubated up to 72 hrs by Cell-Titre Glo assay [PMID: 33650861]
MCF7 IC50 45.6 μM Antiproliferative activity against human MCF7 cells after 48 hrs by CellTiter-GloTM assay [PMID: 22464132]
MDA-MB-231 IC50 3 μM Anticancer activity against human MDA-MB-231 cells assessed as cell growth inhibition incubated up to 72 hrs by Cell-Titre Glo assay [PMID: 33650861]
Sf9 IC50 0.583 μM Inhibition of His-tagged RSK2 expressed in Sf9 cells using ERalpha-Ser167 RLASTND as substrate after 120 mins by chemiluminescence assay [PMID: 22464132]
Sf9 IC50 0.99 μM Inhibition of recombinant RSK2 (unknown origin) expressed in baculovirus infected Sf9 cells assessed as decrease in substrate phosphorylation using GST-fusion protein containing ERalpha-Ser167 sequence-RLASTND as substrate by chemiluminescence analysis [PMID: 23519677]
Sf9 IC50 89 nM Inhibition of his-tagged active RSK2 (unknown origin) expressed in Sf9 cells after 10 to 45 mins by ELISA [PMID: 25147152]

SL 0101-1 Research Summary

This section summarizes 2 in vitro studies and 1 in vivo study of SL 0101-1 from 2 published references. In vitro models include recombinant murine RSK2 N-terminal kinase domain, residues 45–346; human MCF-7 breast cancer cells. In vivo models include male CD-1 mice.

SL 0101-1 In Vitro Studies

In MCF-7 cells, 48 h SL0101 treatment reduced an ATP-based proliferation readout at higher tested concentrations. This assay alone does not establish cancer-cell selectivity or distinguish growth arrest from loss of viability. [2]

Structural binding of SL0101 to the murine RSK2 N-terminal domain

Biochemical assay · Recombinant murine RSK2 N-terminal kinase domain, residues 45–346 [1]

The SL0101 complex showed a reorganized nucleotide-binding cleft forming a hydrophobic pocket. Comparison with the AMP-PNP-bound structure revealed major N-lobe, hinge and αD-helix rearrangements. The structural endpoint does not establish cellular potency or proteome-wide selectivity.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Diffraction/refinement resolutionresolution 1.53 Å[1]
SL0101 binding-pocket architecturestructural observation Reorganized hydrophobic pocket overlapping the nucleotide-binding site[1]

Literature-Reported Treatment Conditions

Method
Co-crystallization of the isolated domain with synthesized SL0101; AMP-PNP-bound structure used for comparison.
Reported limits
This is a structural study; no treatment dose or IC50 is assigned.
Methods and source locations

Compound reported in the paper: SL0101

Evidence concerns the reported SL0101 material; no Adooq lot, purity or supplier equivalence validation is implied.

Figure 1; Experimental Procedures: Inhibitors and Crystallization and Structure Determination; Table 1; Results Overview and binding-mode section; Figures 3 and 6

Diffraction/refinement resolution: X-ray crystallography; one native crystal per dataset; Rwork/Rfree 0.19/0.22. — Table 1, RSK2-SL0101 column and footnotes

SL0101 binding-pocket architecture: Comparison with AMP-PNP-bound domain; ligand omit electron-density map in Figure 6A. — Figures 3 and 6; Results: binding mode

SL0101 reduces the ATP-based proliferation readout in MCF-7 cells

Cell-based study · Human MCF-7 breast cancer cells [2]

SL0101 lowered the vehicle-normalized proliferation readout at higher tested concentrations after 48 h. The endpoint was ATP content rather than a direct cell count. Analogue 7 was more active in the same assay; its results are not assigned to SL0101.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
ATP-based proliferation relative to vehiclequalitative concentration response Reduced at higher concentrations in the series extending to 50 μM; n = 3 in quadruplicate; bars = SD[2]

Literature-Reported Treatment Conditions

Treatment concentration
Concentration series up to 50 μM
Exposure duration
48 h
Method
CellTiter-Glo assay after compound or vehicle treatment
Vehicle
Vehicle-treated cells were the normalization control; composition is not specified in the relevant proliferation methods.
Co-treatment
None; analogue 7 was a parallel comparator, not a cotreatment.
Reported limits
Exact vehicle composition and a fitted parent-compound cellular IC50 are not provided in the selected Figure 3/Proliferation Assays text.
Methods and source locations

Compound reported in the paper: SL0101; Compound label in the paper: Compound 1

Evidence concerns the reported SL0101 material; no Adooq lot, purity or supplier equivalence validation is implied.

Figure 1; Figure 3 and caption; cellular Results; official SI PDF page 2, Proliferation Assays

ATP-based proliferation relative to vehicle: CellTiter-Glo; compound or vehicle added 24 h after seeding; ATP measured 48 h after addition. Figure 3 marks p < 0.05 versus vehicle at higher concentrations (Student’s t test). No exact curve values or fitted IC50 extracted. — Figure 3 and caption; SI page 2, Proliferation Assays

SL 0101-1 In Vivo Studies

In male CD-1 mice, single intravenous and intraperitoneal SL0101 doses produced plasma half-lives of 0.15 h and 0.40 h, respectively. This short systemic exposure is a limitation for interpreting animal studies and does not establish antitumor efficacy. [2]

Short plasma half-life after systemic SL0101 dosing in mice

Animal study · Male CD-1 mice [2]

Both routes yielded plasma half-lives below 30 min. These results delimit systemic exposure under the tested formulation; they do not establish lack of activity after direct local delivery.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Plasma elimination half-lifet1/2 0.15 h (1 mg/kg iv); 0.40 h (2.5 mg/kg ip)[2]
Plasma exposureC0 / Cmax C0 = 291 ng/mL (iv); Cmax = 1851 ng/mL (ip)[2]

Conditions shared by the study groups

Frequency
Single administration
Vehicle
Cremophor:EtOH:phosphate-buffered saline, 1:1:15
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
Intravenous SL0101
1 mg/kg
Parallel route/dose characterization; no efficacy-control comparison is claimed.t1/2 0.15 h; extrapolated C0 291 ng/mL.[2]
Intraperitoneal SL0101
2.5 mg/kg
Parallel route/dose characterization; no efficacy-control comparison is claimed.t1/2 0.40 h; Cmax 1851 ng/mL.[2]
Intravenous SL0101
Model: Male CD-1 mice
Route: Intravenous
Reported limits: Animal number, sampling schedule and bioanalytical validation details are not specified in main Table 1 or the SI In vivo studies paragraph.
Intraperitoneal SL0101
Model: Male CD-1 mice
Route: Intraperitoneal
Reported limits: Animal number, sampling schedule and bioanalytical validation details are not specified in main Table 1 or the SI In vivo studies paragraph.
Methods and source locations

Compound reported in the paper: SL0101; Compound label in the paper: Compound 1

Evidence concerns the reported SL0101 material; no Adooq lot, purity or supplier equivalence validation is implied.

Figure 1; pharmacokinetic Results paragraph; Table 1 and footnote; official SI PDF page 2, In vivo studies

Plasma elimination half-life: Single-dose pharmacokinetic analysis; no uncertainty estimates or n given in Table 1. — Table 1, t1/2 column

Plasma exposure: C0 is extrapolated to time zero; Cmax is the maximum plasma concentration. These are distinct reported metrics. — Table 1, C0 and Cmax columns and footnote

Intravenous SL0101 · Figure 1; pharmacokinetic Results paragraph; Table 1 and footnote; official SI PDF page 2, In vivo studies

Intraperitoneal SL0101 · Figure 1; pharmacokinetic Results paragraph; Table 1 and footnote; official SI PDF page 2, In vivo studies

Specifications

Manufacturer Adooq Bioscience
Actions Inhibitor
CAS Number 77307-50-7
Applications RSK Inhibitor
Formula C25H24O12
Molecular Weight 516.45
SMILES
C[C@H]1[C@@H]([C@H]([C@H]([C@@H](O1)OC2=C(OC3=CC(=CC(=C3C2=O)O)O)C4=CC=C(C=C4)O)O)OC(=O)C)OC(=O)C

Storage & Solubility

In Vitro Solubility

Reported Solubility

No reported solubility data are available for this product.

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

SL 0101-1 Research References

  1. [1] Utepbergenov D, Derewenda U, Olekhnovich N, et al. Insights into the inhibition of the p90 ribosomal S6 kinase (RSK) by the flavonol glycoside SL0101 from the 1.5 Å crystal structure of the N-terminal domain of RSK2 with bound inhibitor Biochemistry (2012). PMID: 22846040 DOI: 10.1021/bi300620c Source material
  2. [2] Mrozowski RM, Vemula R, Wu B, et al. Improving the affinity of SL0101 for RSK using structure-based design ACS Med Chem Lett (2013). PMID: 23519677 DOI: 10.1021/ml300298v Source material

Publications

1 publication citing this product

  1. Pirbhoy PS, .et al. , Learn Mem, 2017, Aug; 24(8): 341-357 PMID: 28716954

Added to your cart

View Cart Checkout
Loading...